• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • NORTH AMERICA EDITION
      Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • NORTH AMERICA EDITION
      North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Life Science Market
    Life Science News
    Life Science Stocks
    • Life Science Market
    • Life Science News
    • Life Science Stocks

    Northwest Medical Isotopes to Build Moly-99 Production Facility

    Charlotte McLeod
    May. 08, 2014 04:37PM PST
    Life Science Investing News

    The Columbia Daily Tribune reported that Northwest Medical Isotopes LLC plans to build a facility at the University of Missouri’s Discovery Ridge Research Park that will produce molybdenum-99.

    The Columbia Daily Tribune reported that Northwest Medical Isotopes LLC plans to build a facility at the University of Missouri’s Discovery Ridge Research Park that will produce molybdenum-99.

    Moly-99 is used by radio pharmacies to produce technetium-99m, which in turn is used in “nuclear imaging studies, including medical diagnostic tests for heart, bone and kidney disease as well as cancer.”

    As quoted in the market news:

    Of the two ‘critical markets’ for molybdenum-99, one is Mallinckrodt Pharmaceuticals, which is in north St. Louis County. The other company is in Boston. These companies use molybdenum-99 to produce the necessary medical radioisotope for imaging studies.

    ‘The United States is currently reliant upon two sources of this critical imaging tracer,’ [Nick Fowler, founder and CEO of Northwest Medical Isotopes,] said. ‘One is being decommissioned in 2016, and the other is being retooled in 2017 or 2018, meaning the U.S. supply is at significant risk. This is a huge, important diagnostic tool to cardiologists and oncologists.’

    Fowler said he hopes this facility will ‘fill an anticipated void’ in the isotope production industry.

    Click here to read the full Columbia Daily Tribune report.

    diagnostic tests
    The Conversation (0)

    Go Deeper

    AI Powered
    Uranium Outlook: Australia Edition

    Uranium Outlook: Australia Edition

    Molybdenum Mining in Canada

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×